1676 related articles for article (PubMed ID: 34737266)
1. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.
Weigang S; Fuchs J; Zimmer G; Schnepf D; Kern L; Beer J; Luxenburger H; Ankerhold J; Falcone V; Kemming J; Hofmann M; Thimme R; Neumann-Haefelin C; Ulferts S; Grosse R; Hornuss D; Tanriver Y; Rieg S; Wagner D; Huzly D; Schwemmle M; Panning M; Kochs G
Nat Commun; 2021 Nov; 12(1):6405. PubMed ID: 34737266
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
[TBL] [Abstract][Full Text] [Related]
5. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
6. The great escape? SARS-CoV-2 variants evading neutralizing responses.
Prévost J; Finzi A
Cell Host Microbe; 2021 Mar; 29(3):322-324. PubMed ID: 33705702
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
[TBL] [Abstract][Full Text] [Related]
8. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
Wahid M; Jawed A; Mandal RK; Dailah HG; Janahi EM; Dhama K; Somvanshi P; Haque S
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5857-5864. PubMed ID: 34604978
[TBL] [Abstract][Full Text] [Related]
9. Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential.
Kubik S; Arrigo N; Bonet J; Xu Z
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834921
[TBL] [Abstract][Full Text] [Related]
10. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
[TBL] [Abstract][Full Text] [Related]
11. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.
Zhang L; Li Q; Liang Z; Li T; Liu S; Cui Q; Nie J; Wu Q; Qu X; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):1-5. PubMed ID: 34890524
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Hoffmann M; Arora P; Groß R; Seidel A; Hörnich BF; Hahn AS; Krüger N; Graichen L; Hofmann-Winkler H; Kempf A; Winkler MS; Schulz S; Jäck HM; Jahrsdörfer B; Schrezenmeier H; Müller M; Kleger A; Münch J; Pöhlmann S
Cell; 2021 Apr; 184(9):2384-2393.e12. PubMed ID: 33794143
[TBL] [Abstract][Full Text] [Related]
14. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
15. Antibody escape and global spread of SARS-CoV-2 lineage A.27.
Kaleta T; Kern L; Hong SL; Hölzer M; Kochs G; Beer J; Schnepf D; Schwemmle M; Bollen N; Kolb P; Huber M; Ulferts S; Weigang S; Dudas G; Wittig A; Jaki L; Padane A; Lagare A; Salou M; Ozer EA; Nnaemeka N; Odoom JK; Rutayisire R; Benkahla A; Akoua-Koffi C; Ouedraogo AS; Simon-Lorière E; Enouf V; Kröger S; Calvignac-Spencer S; Baele G; Panning M; Fuchs J
Nat Commun; 2022 Mar; 13(1):1152. PubMed ID: 35241661
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.
Cele S; Karim F; Lustig G; San JE; Hermanus T; Tegally H; Snyman J; Moyo-Gwete T; Wilkinson E; Bernstein M; Khan K; Hwa SH; Tilles SW; Singh L; Giandhari J; Mthabela N; Mazibuko M; Ganga Y; Gosnell BI; Karim SSA; Hanekom W; Van Voorhis WC; Ndung'u T; ; Lessells RJ; Moore PL; Moosa MS; de Oliveira T; Sigal A
Cell Host Microbe; 2022 Feb; 30(2):154-162.e5. PubMed ID: 35120605
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
Clark SA; Clark LE; Pan J; Coscia A; McKay LGA; Shankar S; Johnson RI; Brusic V; Choudhary MC; Regan J; Li JZ; Griffiths A; Abraham J
Cell; 2021 May; 184(10):2605-2617.e18. PubMed ID: 33831372
[TBL] [Abstract][Full Text] [Related]
18. De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients.
Simons LM; Ozer EA; Gambut S; Dean TJ; Zhang L; Bhimalli P; Schneider JR; Mamede JI; Ison MG; Karmali R; Gordon LI; Lorenzo-Redondo R; Hultquist JF
Transpl Infect Dis; 2022 Dec; 24(6):e13914. PubMed ID: 35899968
[TBL] [Abstract][Full Text] [Related]
19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.
Ruiz-Rodriguez P; Francés-Gómez C; Chiner-Oms Á; López MG; Jiménez-Serrano S; Cancino-Muñoz I; Ruiz-Hueso P; Torres-Puente M; Bracho MA; D'Auria G; Martinez-Priego L; Guerreiro M; Montero-Alonso M; Gómez MD; Piñana JL; ; González-Candelas F; Comas I; Marina A; Geller R; Coscolla M
mBio; 2021 Dec; 12(6):e0231521. PubMed ID: 34781748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
